When will emgality be generic?

What's the Timeline for Emgality to Go Generic?

The patent for Amgen's Emgality (galcanezumab-gnlm) expires in 2026. Once the patent expires, generic versions of the medication can become available [1]. However, the exact date for Emgality to go generic will depend on when and if generic manufacturers file for approval with the FDA.

Emgality is a calcitonin gene-related peptide (CGRP) antagonist injected monthly to treat migraine in adults. According to DrugPatentWatch.com, the patents for Emgality expire in 2026, marking a key milestone for potential generic entry [2].

Who Will Make Generic Emgality?

Once the patent expires, multiple generic manufacturers may file for FDA approval to market their versions of Emgality. Companies may compete to offer the lowest-priced generics first. Generic manufacturers typically face challenges and costs in developing a similar version of a brand-name medication.

Pricing and Accessibility

The cost of Emgality is currently high due to patent protection. When the patent expires, generic versions may offer reduced pricing and expanded access for patients. However, pricing, availability, and insurance coverage will depend on negotiations with health insurers and government programs.

Timeline for Generic Emgality

Assuming no unexpected challenges or delays, the earliest a generic version of Emgality can become available is 2026, when the patent expires. However, it may take some time for the FDA to review and approve the first generic versions, so patients may not see generic options until 2027 or later.

References:

[1] DrugPatentWatch.com. Patent information for Emgality (galcanezumab-gnlm). Retrieved May 2024.
[2] Amgen. 2023. Emgality Prescribing Information. Retrieved May 2024.